Agile Therapeutics

Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
Sponsored
Agile Therapeutics (NASDAQ: AGRX) Upgraded To "Buy" Rating By Analysts At Maxim Group
Sponsored
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
Sponsored
Agile Therapeutics (NASDAQ: AGRX) Upgraded To "Buy" Rating By Analysts At Maxim Group
Sponsored
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
Sponsored
This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions Of Women Thanks To A Partnership With Afaxys
Sponsored
Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women
Sponsored

Agile Therapeutics Recent News

This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023
Agile Therapeutics (NASDAQ: AGRX) announced the closing of its public offering in May.
Sponsored
Agile Therapeutics – This Women's Healthcare Company's "Skinfusion" Technology Sets It Apart From Other Contraceptive Companies
Al Altomari, Chairman & CEO of Agile Therapeutics (NASDAQ: AGRX) was recently interviewed by Benzinga. 
Sponsored
Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 – What Is The Hype All About?
Women are itching for more birth control options that cater to their unique needs and preferences. While traditional forms of birth control – such as the pill and condoms – have been reliable options for many years, they don’t satisfy everyone.
Sponsored
The Overturning of Roe v. Wade Has Changed The Landscape Of Birth Control; Smaller Companies Are Now An Integral Part Of Care
The invention of birth control in the 1960s revolutionized women's health and their lives. In 2022, the contraceptive market was valued at $8.3 billion and it is projected to grow at a compound annual growth rate (CAGR) of around 5.16% from 2023 to 2030.
Sponsored
Agile Therapeutics: The CEO Of This Women's Healthcare Company That Recently Saw Revenue Growth Of 33% Speaks To Benzinga
Al Altomari, Chairman & CEO of Agile Therapeutics (NASDAQ: AGRX) was recently a guest on Benzinga’s All Access.
Sponsored
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
Al Altomari, Chairman and CEO of Agile Therapeutics Inc (NASDAQ: AGRX), was recently interviewed by Benzinga.
Sponsored
This Biotech Company is Pursuing Positive Cash Flow In 2023
Biotech company Agile Therapeutics Inc. (NASDAQ: AGRX) began selling its contraceptive patch in 2021, and the company is pursuing positive cash flow by the end of 2023. 
Sponsored
Women's Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow
Agile Therapeutics Inc. (NASDAQ: AGRX) is on a journey to fulfill the unmet health needs of women with products designed to provide them with contraceptive options.
Sponsored
Can This Company's Birth Control Patch Disrupt The Contraceptive Market?
From Evofem Biosciences Inc.’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc.’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive, the market is never in short supply of birth control products.
Sponsored
The Past Week's Notable Insider Buys Included Digitalbridge, Life Time, A SPAC And More
Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain. With the new earnings season underway, this week's most notable insider purchases were made by 10% owners.
Agile Therapeutics Plunges After Company Prices A Stock Offering At $6.35 Per Share

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved